Warning: The NCBI web site requires JavaScript to function. more...
The therapeutic importance of understanding mechanisms of neuronal cell death in neurodegenerative disease.
Golde TE.
Mol Neurodegener. 2009 Feb 4;4:8.
Related citations
Regulation of caspases in the nervous system implications for functions in health and disease.
Troy CM, Akpan N, Jean YY.
Prog Mol Biol Transl Sci. 2011;99:265-305. Review.
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS.
Oncologist. 1996;1(5):326-330.
Final Report on Carcinogens Background Document for Styrene.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
Stem cell-based models and therapies for neurodegenerative diseases.
Iyer S, Alsayegh K, Abraham S, Rao RR.
Crit Rev Biomed Eng. 2009;37(4-5):321-53. Review.
Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.
Adv Exp Med Biol. 2007;608:1-22. Review.
Cell death mechanisms in neurodegeneration.
Jellinger KA.
J Cell Mol Med. 2001 Jan-Mar;5(1):1-17. Review.
Treatment of Parkinson's disease : what's on the horizon?
Wu SS, Frucht SJ.
CNS Drugs. 2005;19(9):723-43. Review.
Why pleiotropic interventions are needed for Alzheimer's disease.
Frautschy SA, Cole GM.
Mol Neurobiol. 2010 Jun;41(2-3):392-409. Epub 2010 May 2. Review.
The enigma of cell death in neurodegenerative disorders.
Jellinger KA, Stadelmann CH.
J Neural Transm Suppl. 2000;(60):21-36.
Targeting Abeta and tau in Alzheimer's disease, an early interim report.
Golde TE, Petrucelli L, Lewis J.
Exp Neurol. 2010 Jun;223(2):252-66. Epub 2009 Aug 27. Review.
Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
Lipton SA, Gu Z, Nakamura T.
Int Rev Neurobiol. 2007;82:1-27. Review.
Potentials of ES cell therapy in neurodegenerative diseases.
Srivastava AS, Malhotra R, Sharp J, Berggren T.
Curr Pharm Des. 2008;14(36):3873-9. Review.
The 'Sentinel Node' Concept: More Questions Raised than Answers Provided?
Schlag PM.
Oncologist. 1998;3(5):VI-VII.
Guidelines, editors, pharma and the biological paradigm shift.
Singh AR, Singh SA.
Mens Sana Monogr. 2007 Jan;5(1):27-30.
Apoptosis and neurologic disease.
Honig LS, Rosenberg RN.
Am J Med. 2000 Mar;108(4):317-30. Review.
New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists.
Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, Rogers JT, Ovadia H, Lahiri DK.
Ann N Y Acad Sci. 2004 Dec;1035:290-315. Review.
Axon degeneration in Parkinson's disease.
Burke RE, O'Malley K.
Exp Neurol. 2012 Jan 18. [Epub ahead of print]
Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ, Figgitt DP.
CNS Drugs. 2004;18(6):379-96. Review.
Apoptotic mechanisms involved in neurodegenerative diseases: experimental and therapeutic approaches.
Camins A, Pallas M, Silvestre JS.
Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):43-65. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on